Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer

Regorafenib and trifluridine/tipiracil (TAS-102) are novel antitumor agents for patients with refractory metastatic colorectal cancer. However, it is unclear which patients may derive a survival benefit from these drugs in real-life clinical practice. We evaluated retrospectively the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Akira, Sadahiro, Sotaro, Suzuki, Toshiyuki, Okada, Kazutake, Saito, Gota, Miyakita, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176362/
https://www.ncbi.nlm.nih.gov/pubmed/30344762
http://dx.doi.org/10.3892/ol.2018.9421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176362/
https://www.ncbi.nlm.nih.gov/pubmed/30344762
http://dx.doi.org/10.3892/ol.2018.9421

Ejemplares similares